News
Nucana Biomed signs an exclusive, world-wide, licence to develop its ProTide technology in cancer
Released: Wednesday 18th November 2009
NuCana BioMed Ltd ("NuCana") and Morvus Technology Ltd ("Morvus") today announce that an agreement has been signed by which Morvus has granted to NuCana an exclusive, world-wide, licence with rights to develop its ProTide technology for the enhancement of nucleoside analogues ("nucleosides"). These are important drugs used in the treatment of many common cancers and in 2008 the top-selling drug of this type, Gemzar® (gemcitabine: Eli Lilly) had world-wide sales of over $1.7billion.
NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. The NuCana BioMed management team has a successful track record of building virtual biopharmaceutical organisations to global integrated companies.
Morvus Technology is a privately-owned company engaged in the discovery, development and commercialisation of novel drugs for the oncology market. The Company was established in 2004 and has offices and laboratories near Llanarthe, South Wales. Morvus has a broad portfolio of technology which is focused on disease areas for which there is a clear, unmet medical need.
